A Randomized Phase II Trial of Paclitaxel and Bevacizumab Versus Gemcitabine, Paclitaxel, and Bevacizumab as First Line Treatment for Locally Advanced or Metastatic Breast Cancer
A Randomized Phase II Trial of Paclitaxel and Bevacizumab Versus Gemcitabine, Paclitaxel, and Bevacizumab as First Line Treatment for Locally Advanced or Metastatic Breast Cancer
This study will compare the cancer response to both treatments for locally advanced or metastatic breast cancer
Inclusion Criteria:
Exclusion
Criteria:
Fayetteville, Arkansas 72703, United States
La Jolla, California 92037, United States
Mission Hills, California 91345, United States
Santa Rosa, California 95403, United States
Denver, Colorado 80218, United States
Fort Myers, Florida 33916, United States
Miami, Florida 33136, United States
Miami Beach, Florida 33140, United States
Orlando, Florida 32806, United States
Atlanta, Georgia 30322, United States
Springfield, Illinois 62703, United States
Muncie, Indiana 47303, United States
Lexington, Kentucky 40536, United States
Southfield, Michigan 48075, United States
Chesterfield, Missouri 63017, United States
Missoula, Montana 59807, United States
Akron, Ohio 44302, United States
Dayton, Ohio 45429, United States
Oklahoma City, Oklahoma 73104, United States
Dunmore, Pennsylvania 18512, United States
Pittsburgh, Pennsylvania 15213, United States
Knoxville, Tennessee 37916, United States
Memphis, Tennessee 38138, United States
Nashville, Tennessee 37203, United States
Dallas, Texas 75237, United States
Lubbock, Texas 79415, United States
Richmond, Virginia 23230, United States
Everett, Washington 98201, United States
Madison, Wisconsin 53717, United States
Milwaukee, Wisconsin 53226, United States
Ponce, 00716, Puerto Rico